Vectibix

Panitumumab

In combination w/ oxaliplatin-based or irinotecan-based chemotherapy for patients w/ wild-type RAS metastatic CRC (mCRC). Monotherapy for patients w/ wild-type RAS (mCRC) after standard chemotherapy failure.

IV infusion Recommended dose: Prior to infusion, dilute to 0.9% NaCl to final conc not to exceed 10 mg/mL. 6 mg/kg once every 2 wk. Recommended infusion time: Approx 60 min. Doses >1,000 mg should be infused over approx 90 min.

History of life-threatening hypersensitivity. Patients w/ mutant RAS mCRC or unknown RAS status in combination w/ oxaliplatin-based chemotherapy.

Not to be administered as IV push or bolus. Not indicated for 1st line mCRC in combination w/ bevacizumab & oxaliplatin-containing or irinotecan-containing chemotherapy. Discontinue if dermatologic & soft tissue toxicity associated w/ severe or life-threatening inflammatory or infectious complications occur. Permanently discontinue if severe, persistent or life-threatening infusion reaction; severe &/or persistent hypersensitivity reactions occur; in confirmed ILD. Monitor for development of inflammatory or infectious sequelae in patients who develop dermatologic or soft tissue toxicities while on treatment; evidence of keratitis, ulcerative keratitis, or corneal perforation; hypomagnesaemia & accompanying hypocalcaemia prior to initiating treatment, & periodically during treatment & for up to 8 wk after completion of treatment. Necrotising fasciitis &/or sepsis. SJS, TEN. Severe hypomagnesaemia; hypokalaemia. Patients w/ history or evidence of interstitial pneumonitis or pulmonary fibrosis; w/ ECOG 2 performance status in combination w/ chemotherapy. Wear sunscreen, hat & limit sun exposure during therapy. Determine mutational status prior to initiation of therapy. Avoid combination w/ irinotecan, bolus 5-fluorouracil & leucovorin chemotherapy. May affect ability to drive & use machines. Acute renal failure in patients who develop severe diarrhea & dehydration. Women of childbearing potential should use contraceptive measures during treatment & for 2 mth after last dose. Avoid becoming pregnant. Discontinue lactation during therapy & for 2 mth after last dose. Ped. Increased number of serious adverse events in elderly patients treated in combination w/ irinotecan or oxaliplatin-based chemotherapy.

Diarrhea, nausea, vomiting, constipation, abdominal pain, constipation, stomatitis; fatigue, pyrexia, asthenia, mucosal inflammation, peripheral edema; paronychia, conjunctivitis; decreased wt; decreased appetite, hypomagnesemia, hypokalemia; back pain; paresthesia; insomnia; dyspnea, cough; rash, dermatitis acneiform, pruritus, erythema, dry skin, skin fissures, acne, alopecia. Leukopenia; increased lacrimation, dry eye, eyelash growth, blepharitis, ocular hyperemia, eye irritation & pruritus; dyspepsia, dry mouth, rectal hemorrhage, GERD, lower abdominal pain, aphthous ulcer, oral pain, cheilitis; pain, chills; hypersensitivity; UTI, pustular rash, folliculitis, cellulitis, localized infection; decreased blood Mg; dehydration, hypocalcemia, hyperglycemia, hypophosphatemia; pain in extremity; headache, dizziness; anxiety; epistaxis, pulmonary embolism; exfoliative, papular, erythematous, macular, maculopapular, pruritic, & generalized rash, nail disorder, skin exfoliation, ulcer, toxicity, pain, & lesion, palmar-plantar erythrodysesthesia syndrome, scab, hyperhidrosis, hypertrichosis, onychoclasis, abnormal hair growth, dermatitis; DVT, flushing. SJS, TEN.

Targeted Cancer Therapy

L01FE02 - panitumumab ; Belongs to the class of EGFR (Epidermal Growth Factor Receptor) inhibitors. Used in the treatment of cancer.

S